![Luc St-Onge](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Luc St-Onge
Corporate Officer/Principal chez Licensing Executives Society
Postes actifs de Luc St-Onge
Sociétés | Poste | Début | Fin |
---|---|---|---|
Licensing Executives Society | Corporate Officer/Principal | - | - |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - | - |
Historique de carrière de Luc St-Onge
Anciens postes connus de Luc St-Onge
Sociétés | Poste | Début | Fin |
---|---|---|---|
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - | - |
Max Planck Gesellschaft zur Förderung der Wissenschaften eV
![]() Max Planck Gesellschaft zur Förderung der Wissenschaften eV Investment Trusts/Mutual FundsMiscellaneous Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is a non-profit organization headquartered in Munich, Germany. The firm was founded in 1948 as a successor organization to the Kaiser Wilhelm Society. MPG conducts basic research in the natural sciences, life sciences, and humanities and provides investment advisory services to foundations. | Corporate Officer/Principal | - | - |
Affectis Pharmaceuticals AG
![]() Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Corporate Officer/Principal | 06/11/2009 | - |
Formation de Luc St-Onge
University of Sherbrooke | Doctorate Degree |
Statistiques
Internationale
Allemagne | 5 |
Canada | 2 |
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 5 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Miscellaneous | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 5 |
---|---|
Affectis Pharmaceuticals AG
![]() Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Health Technology |
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Licensing Executives Society | |
Pharma-Lizenz-Club Deutschland | |
Max Planck Gesellschaft zur Förderung der Wissenschaften eV
![]() Max Planck Gesellschaft zur Förderung der Wissenschaften eV Investment Trusts/Mutual FundsMiscellaneous Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is a non-profit organization headquartered in Munich, Germany. The firm was founded in 1948 as a successor organization to the Kaiser Wilhelm Society. MPG conducts basic research in the natural sciences, life sciences, and humanities and provides investment advisory services to foundations. | Miscellaneous |
- Bourse
- Insiders
- Luc St-Onge
- Expérience